Elsevier logo

Publisher: Elsevier

Related content
Volume 18, Number 4, July 1996

< previous issue | all issues | next issue >

Editorial comment
pp. 561-561(1)
Author: Krosnick A.

Etiologies and sequelae of excessive daytime sleepiness
pp. 562-576(15)
Authors: Roth T.; Roehrs T.A.

Editorial comment
pp. 577-577(1)
Author: Krosnick A.

Editorial comment
pp. 591-591(1)
Author: Krosnick A.

Changing antipsychotic medication: guidelines on the transition to treatment with Risperidone
pp. 592-607(16)
Authors: Borison R.L.; Consensus Study Group on Risperidone Dosing

Efficacy and safety of cefdinir in the treatment of patients with acute bronchitis
pp. 626-634(9)
Authors: Sperling M.J.; Puopolo A.; Griffin T.J.; Keyserling C.H.; Tack K.J.; Behalf of the Cefdinir Bronchitis Study Group

Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study
pp. 635-646(12)
Authors: Wolfe J.D.; Selner J.C.; Mendelson L.M.; Hampel F.; Schaberg A.

Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer
pp. 647-657(11)
Authors: Sharifi R.; Bruskewitz R.C.; Gittleman M.C.; Graham S.D.; Hudson P.B.; Stein B.

The CARE study: a postmarketing evaluation of ramipril in 11,100 patients
pp. 658-670(13)
Authors: Kaplan N.M.; Clinical AltaceR Real-World Efficacy CARE Investigators

Effective administration methods and dosages of interferon therapy for chronic hepatitis C
pp. 671-679(9)
Authors: Nomura H.; Kimura Y.; Tada H.; Hisano C.; Morita C.; Okamoto O.; Shiraishi G.; Higashi M.; Kashiwagi S.

Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX(R) STATdose&unknown; System
pp. 687-699(13)
Authors: Mushet G.R.; Cady R.K.; Camak Baker C.; Clements B.; Gutterman D.L.; Davis R.

Pharmaceutical economics & health policy - Editorial comment
pp. 702-702(1)
Author: Alexander Sclar D.

Profitability, third-party reimbursement, and access to community pharmacies
pp. 703-715(13)
Authors: Carroll N.V.; Miederhoff P.A.; Waters L.W.

The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost
pp. 716-725(10)
Authors: Hotchkies L.; Grima D.T.; Hedayati S.

Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model
pp. 757-777(21)
Authors: Marchetti A.; Tak Piech C.; McGhan W.F.; Neugut A.I.; Smith B.T.

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life
pp. 778-788(11)
Authors: Crucitt M.A.; Hyman W.; Grote T.; Tester W.; Madajewicz S.; Yee S.; Wentz A.; Griffin D.; Parasuraman T.V.; Bryson J.

< previous issue | all issues | next issue >

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page